Park Avenue Securities LLC bought a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) during the 3rd quarter, HoldingsChannel.com reports. The fund bought 11,850 shares of the company’s stock, valued at approximately $96,000.
Several other institutional investors have also made changes to their positions in the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of Teva Pharmaceutical Industries by 15.3% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 340,665 shares of the company’s stock worth $2,749,000 after acquiring an additional 45,149 shares in the last quarter. Pinnacle Associates Ltd. increased its position in shares of Teva Pharmaceutical Industries by 208.9% in the third quarter. Pinnacle Associates Ltd. now owns 53,675 shares of the company’s stock worth $433,000 after acquiring an additional 36,300 shares in the last quarter. Monaco Asset Management SAM acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth approximately $1,081,000. Meitav Dash Investments Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries by 122.7% during the third quarter. Meitav Dash Investments Ltd. now owns 2,677,358 shares of the company’s stock worth $20,944,000 after purchasing an additional 1,474,889 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries by 9.5% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 21,380,200 shares of the company’s stock worth $172,533,000 after purchasing an additional 1,847,280 shares during the period. 50.39% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several analysts recently commented on the stock. UBS Group cut shares of Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating in a report on Friday, November 4th. JPMorgan Chase & Co. cut shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and decreased their price target for the stock from $11.00 to $10.00 in a report on Monday, November 14th. Piper Sandler decreased their price target on shares of Teva Pharmaceutical Industries from $8.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday, November 23rd. Jefferies Financial Group cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating and raised their price target for the stock from $10.00 to $12.00 in a report on Thursday, January 19th. Finally, StockNews.com began coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 12th. They issued a “buy” rating for the company. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $10.67.
Teva Pharmaceutical Industries Price Performance
Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last issued its quarterly earnings data on Thursday, November 3rd. The company reported $0.56 earnings per share for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). Teva Pharmaceutical Industries had a positive return on equity of 26.97% and a negative net margin of 8.52%. The firm had revenue of $3.60 billion during the quarter, compared to analyst estimates of $3.86 billion. On average, sell-side analysts expect that Teva Pharmaceutical Industries Limited will post 2.4 earnings per share for the current year.
Teva Pharmaceutical Industries Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.
- Get a free copy of the StockNews.com research report on Teva Pharmaceutical Industries (TEVA)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.